Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...

Eli Lilly reported full results from its phase 2 SYNERGY-MASH trial of GLP-1 and GIP agonist tirzepatide – already on the market as Mounjaro for diabetes and Zepbound for obesity – in biopsy ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...

Lilly inks a global licensing deal with OliX for OLX75016, a Phase 1 candidate targeting MASH and other cardiometabolic conditions. NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts On ...

To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).